Absci logo

Absci

absci.com

Absci uses generative AI and an integrated drug creation platform to design and optimize biologic drugs, including antibodies, for pharmaceutical companies and patients. Its technology combines AI-driven de novo design, lead optimization, and wet lab validation to create therapeutics against difficult-to-drug targets, aiming to accelerate the development of better biologics for challenging diseases.

Facts

HQ
Vancouver, Wash.
Sectors
Biotechnology Research
Founded
2011
Employees
159
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

Washougal-based Resect AI Raises $25 Million as Southwest Washington Startups Attract More Venture Capital

Resect AI in Washougal has secured $25 million in venture capital as part of growing venture interest in Southwest Washington startups, joining a regional trend of local firms attracting major funding despite limited institutional VC presence. Angel investors and emerging local funds, along with connections to Portland and Seattle firms, are helping startups like Digs and others access capital, mentorship and recruiting support.

See all 31 stories, episodes and videos about Absci.

People

See all 5
  • Sean McClain Founder, CEO & Director
  • Sean McClain CEO and Founder
  • Sean McClain Founder and CEO

Online